Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Susanne Windhagen"'
Autor:
Tobias Ruck, Andreas Schulte-Mecklenbeck, Steffen Pfeuffer, Michael Heming, Luisa Klotz, Susanne Windhagen, Christoph Kleinschnitz, Catharina C. Gross, Heinz Wiendl, Sven G. Meuth
Publikováno v:
EBioMedicine, Vol 46, Iss , Pp 381-386 (2019)
Background: Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect t
Externí odkaz:
https://doaj.org/article/0e6dc525264646878bcf787490454b7f
Autor:
Andreas Schulte-Mecklenbeck, Heinz Wiendl, Catharina C. Gross, Sven G. Meuth, Christoph Kleinschnitz, Michael Heming, Tobias Ruck, Steffen Pfeuffer, Susanne Windhagen, Luisa Klotz
Publikováno v:
EBioMedicine
Background Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e7d7c613f01112c3526480d2b1dc1a
https://doi.org/10.1016/j.ebiom.2019.07.062
https://doi.org/10.1016/j.ebiom.2019.07.062
Autor:
Luisa Klotz, Christine Lebrun-Frenay, Jean Pelletier, Guillaume Mathey, Damien Biotti, Pierre Clavelou, Tilman Schneider-Hohendorf, Lise Scandella, Nicholas Schwab, Catharina C. Gross, Patrick Ostkamp, Florence Bucciarelli, Béatrice Pignolet, Ingrid Meinl, David Brassat, Sven G. Meuth, Jonathan Ciron, Florian Deisenhammer, Susanne Windhagen, Heinz Wiendl
Publikováno v:
Neurology
Neurology, American Academy of Neurology, 2019, 93 (12), pp.550-554. ⟨10.1212/WNL.0000000000008135⟩
Neurology, American Academy of Neurology, 2019, 93 (12), pp.550-554. ⟨10.1212/WNL.0000000000008135⟩
Low l-selectin (CD62L) on CD4+ T cells after cryopreservation has been introduced in 2013 as a risk biomarker for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment1 or HIV infection.2 The biomarker has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda01662c9a82c948c50e0cf52c85e39
https://hal.archives-ouvertes.fr/hal-03001614
https://hal.archives-ouvertes.fr/hal-03001614
Autor:
Ilske Oschlies, Sven G. Meuth, Tobias Ruck, H. Pavenstädt, Steffen Pfeuffer, Leoni Rolfes, Heinz Wiendl, Susanne Windhagen, Linus Angenendt, Julia Krämer
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Alemtuzumab is an efficacious therapy for active relapsing-remitting MS (RRMS), but its use is complicated by the potential development of secondary autoimmunity.1 Recent data from phase 3 extension studies confirm thyroid autoimmunity as the most ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aee018eb298c2d65b5905e01db12b95
https://doi.org/10.1212/nxi.0000000000000657
https://doi.org/10.1212/nxi.0000000000000657
Autor:
Christoph Aufenberg, Sebastian Doerck, Michael Lang, Susanne Windhagen, Christoph Kleinschnitz, B. Tackenberg, Marinus Wieshuber, Sven G. Meuth, Refik Pul, Heinz Wiendl, Tobias Ruck, Rene Schmidt, Vera Straeten, Frederike Anne Straeten, Steffen Pfeuffer, Ralf A. Linker, Christian Eienbroeker, Jürgen Haas, De-Hyung Lee, Volker Limmroth, Luisa Klotz, Brigitte Wildemann, Marc Pawlitzki
Publikováno v:
Journal of neurology. 266(1)
Natalizumab (NTZ) was the first approved monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite proven and sustained efficacy, its use is limited by the risk of progressive multifocal leukoencephalopathy (PML)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48107ff6637fce885b34586735d6ba0
https://pubmed.ncbi.nlm.nih.gov/30446966
https://pubmed.ncbi.nlm.nih.gov/30446966
Autor:
Michela Spadaro, Tilman Schneider-Hohendorf, Volker Siffrin, Xavier Montalban, Felix Luessi, Ester Cantó, Reinhard Hohlfeld, Renaud Du Pasquier, Ralf Gold, Frauke Zipp, Antonio Bertolotto, Dennis Görlich, Christoph Kleinschnitz, Nicholas Schwab, Béatrice Pignolet, Johanna Breuer, David Brassat, Anita Posevitz-Fejfar, Tania Kümpfel, Heinz Wiendl, Annett M. Jacobi, Sven G. Meuth, Susanne Windhagen, Björn Tackenberg, Manuel Comabella, Ingrid Meinl
Publikováno v:
Europe PubMed Central
Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a07a77c462dda217134f13728d4066
https://doi.org/10.1177/1352458515607651
https://doi.org/10.1177/1352458515607651
Autor:
Tania Kümpfel, Ruggero Capra, Susan Goelz, Christoph Kleinschnitz, Luisa Imberti, Bruno Brochet, Bernd C. Kieseier, Vera Straeten, Susanne Windhagen, John Foley, David Brassat, Johanna Breuer, Anita Posevitz-Fejfar, Clemens Warnke, Patrick Vermersch, Heinz Wiendl, Kyle Niessen, Sven G. Meuth, Christine Lebrun-Frenay, Dorothea Buck, Joachim Havla, Nicholas Schwab, Kerstin Göbel, Juergen Haas, Vilmos Posevitz, Brigitte Wildemann, Ingrid Meinl, Andrew T. Chan, Tilman Schneider-Hohendorf, Ralf Gold
Publikováno v:
Neurology, 81(10), 865-871. LIPPINCOTT WILLIAMS & WILKINS
To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment.Patients were recruited from 10 European and US cohorts. Of 289 patients with multiple sclerosis (MS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9a44103a0ef9f576703eda2c056ea72
https://doi.org/10.1212/WNL.0b013e3182a351fb
https://doi.org/10.1212/WNL.0b013e3182a351fb
Autor:
Sven G. Meuth, Luisa Klotz, Nico Melzer, Kathrin Schwarte, Catharina C. Gross, Andreas Schulte-Mecklenbeck, Susanne Windhagen, Bettina Graefe, Diana Ahmetspahic, Silke Jörgens, Heinz Wiendl, Judith Alferink, Volker Arolt, Tobias Ruck, Stefanie Scheu
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
Objective: To characterize changes in myeloid and lymphoid innate immune cells in patients with relapsing-remitting multiple sclerosis (MS) during a 6-month follow-up after alemtuzumab treatment. Methods: Circulating innate immune cells including mye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774a117181e9e5a4979145306ba05916
https://doi.org/10.1212/nxi.0000000000000289
https://doi.org/10.1212/nxi.0000000000000289